MindWalk Holdings Corp. (NASDAQ: HYFT) announced preclinical data showing that animals immunized with immunogens designed using its HYFT platform generated antibodies that cross-reacted with antigens from all four dengue serotypes.

The company's HYFT technology computationally identified a pan-serotype dengue target before immunization began. The subsequent animal studies showed that immunogens designed around this predicted target elicited antibodies recognizing all four dengue serotypes, while scrambled-sequence controls did not demonstrate the same cross-serotype recognition.

The results were reproduced across two independent campaigns using different immunogen formats and adjuvants. MindWalk stated this represents the first public evidence that its platform can connect computational predictions to measurable biological outcomes.

Dengue infects an estimated 400 million people annually across four distinct serotypes. Current approved dengue vaccines are limited to previously infected populations due to concerns about antibody-dependent enhancement, where antibodies against one serotype can worsen disease from another serotype.

"When animals immunized with immunogens built around that prediction produced antibodies that recognized antigens from all four dengue serotypes — and scrambled-sequence controls did not — the prediction was supported in a live immunological system," said CEO Jennifer Bath.

The company noted that while the data demonstrate cross-reactive binding, future studies will determine whether these antibodies neutralize the virus and assess their relationship to antibody-dependent enhancement pathways.

MindWalk's platform combines its HYFT pattern identification system with a Knowledge Graph containing biological data and LensAI for analysis. The company is applying similar approaches to influenza and other multi-strain infectious disease programs.